Novel targeted agents for gastric cancer

Table 1 Ongoing phase III trials of targeting agents for the treatment of advanced gastric cancer

ClinicalTrials.gov Identifier	Setting	Location	Masking	Estimated enrollment	Primary endpoint	Arm
NCT00824785	1^st line	UK	Open-label	730	OS	EOX, EOX + panitumumab
NCT01248403	2^nd line	Germany	Double blind	500	OS	Paclitaxel, Paclitaxel + everolimus
NCT01170663	2^nd line	Global	Double blinded	633	OS	Placebo + paclitaxel, Ramucirumab + paclitaxel
NCT00450203	1^st line	UK	Open Label	1100	OS	ECX, ECX + Bevacizumab
NCT00917384	2^nd line	Global	Double blinded	315	OS	Placebo + BSC, Ramucirumab + BSC
NCT01512745	3^rd line	China	Double blinded	500	PFS	Placebo, Apatinib

OS, overall survival; PFS, progression-free survival; EOX, epirubicin, oxaliplatin and capecitabine; ECX, epirubicin, cisplatin and capecitabine.